Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Status:
Active, not recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and
preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral
dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania